Testing blood for antibodies against platelets in new thrombocytopenia
Tests blood samples for platelet-attacking antibodies in adults with new low platelet counts.
Plain-language title generated from the registry record
Registry title: Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis
Key facts
- Where
- Pessac, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a newly found low platelet count who have not started treatment. Blood samples are used to look for platelet antibodies.
- Age
- Over 18 years old.
- Sex
- All sexes can join.
- Disease stage
- Platelet count below 100 G/L, checked twice. False low platelet counts and acute leukemia must be ruled out.
- Earlier treatment
- No treatment started for the low platelet count. 48 hours of corticosteroid therapy is tolerated. No platelet transfusion with effect in the last 7 days.
Main reasons for not taking part
- Secondary ITP
- False thrombocytopenia
- Acute leukemia
- Pregnant or breastfeeding woman
- Person under guardianship, curatorship or other legal protection
Read by machine on 12 November 2026.
Where in France
- CHU de Bordeaux - service de médecine internePessac, FranceContact: Jean-François VIALLARD, ProfTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Bordeaux
- Trial code
- NCT04800458
- Record updated
- 1 June 2026
- Original description
Immune thrombocytopenia (ITP) is an autoimmune disease but, paradoxically, and unlike other autoimmune diseases, antiplatelet antibodies are not used either for the diagnosis of the disease or for its prognosis. ITP is a diagnosis of exclusion retained after elimination of other pathologies leading to a thrombocytopenia. No major study has prospectively evaluated the diagnostic value of the presence of anti-platelet antibodies in the etiological investigation of a thrombocytopenia, nor the impact of platelet antibodies on the course of ITP. The gold standard analysis for the determination of platelet antibodies, is the "monoclonal antibody immobilization of platelet antigens" assay (MAIPA), either direct to detect autoantibodies attached to platelets, or indirect to detect circulating antiplatelet antibodies. Therefore, this work aims to study the contribution of the presence of anti-platelet antibodies detected in MAIPA to determine the autoimmune nature of a thrombocytopenia at diagnosis.Read full original descriptionShow less
Contribution of Anti-platelet Antibodies Identified With" Monoclonal Antibody Immobilization of Platelet Antigens" Assay (MAIPA) in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis
Immune thrombocytopenia (ITP) is an autoimmune disease but, paradoxically, and unlike other autoimmune diseases, antiplatelet antibodies are not used either for the diagnosis of the disease or for its prognosis. ITP is a diagnosis of exclusion retained after elimination of other pathologies leading to a thrombocytopenia. No major study has prospectively evaluated the diagnostic value of the presence of anti-platelet antibodies in the etiological investigation of a thrombocytopenia, nor the impact of platelet antibodies on the course of ITP. The gold standard analysis for the determination of platelet antibodies, is the "monoclonal antibody immobilization of platelet antigens" assay (MAIPA), either direct to detect autoantibodies attached to platelets, or indirect to detect circulating antiplatelet antibodies. Therefore, this work aims to study the contribution of the presence of anti-platelet antibodies detected in MAIPA to determine the autoimmune nature of a thrombocytopenia at diagnosis.
Inclusion: Patient over 18 years old; Patients with thrombocytopenia <100 G/L, checked twice, having ruled out false thrombocytopenia by platelet aggregation and acute leukemia by smear; No treatment started; Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and prior to any review required by the research); Person affiliated or benefiting from a social security scheme.
Exclusion: Patient treated for thrombocytopenia (48 hours of corticosteroid therapy is tolerated and is not an exclusion criteria); Patients who have been transfused with platelets for less than 7 days with efficacy; Secondary ITP; False thrombocytopenia; Patient with acute leukemia; Pregnant or breastfeeding woman; False thrombocytopenia; Patient under guardianship, curatorship or any other legal protection regime.